Nek2 siRNA therapy (Nagoya University)

N/A

Report date: 2024/07/17 15:00:41

Base Information

Drug NameNek2 siRNA therapy (Nagoya University)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionSerine/threonine-protein kinase NEK2 inhibitors
TargetsSerine/threonine-protein kinase NEK2
Therapy Area/IndicationsPancreatic NeoplasmsCholangiocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNagoya University
China Registration ClassN/A

Develop Information

Active CompaniesNagoya University
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsCholangiocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A